WHO Proposes New Mode Of Engaging With Non-State Actors 28/01/2021 Esther Nakkazi The World Health Organization (WHO) aims to make its engagement with non-state actors (non-state actors) more meaningful and efficient with a new proposal to establish a number of NSA fora that would allow exchange with WHO and member state representatives outside of official meetings. The new proposal — which will be tested during the 74th […] Continue reading -> Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Former Director Of Italian Medicines Agency Recognized For Drug Transparency Work 26/02/2020 Editorial team Former general director of the Italian Medicines Agency (AIFA) Luca Li Bassi was awarded the 2019 “International Transparency in Medicines Policies Awards” by the French civil society watchdog group l’Observatoire Médicaments Transparences (the Observatory for Transparency in Medicines), for his efforts in negotiating a milestone World Health Assembly resolution in May 2019 supporting more public […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Italy Publishes National Regulation Requiring Pharma Disclosure Of Public Support For R&D On New Drugs 28/07/2020 Svĕt Lustig Vijay Italy has become the first nation to require pharmaceutical companies to disclose secret data about any public subsidies it may have received for the development of a new drug, during negotiations over drug pricing and reimbursement with national regulatory authorities, according to a decree published Friday in the nation’s official gazette. The decree, following on […] Continue reading -> Former Director Of Italian Medicines Agency Recognized For Drug Transparency Work 26/02/2020 Editorial team Former general director of the Italian Medicines Agency (AIFA) Luca Li Bassi was awarded the 2019 “International Transparency in Medicines Policies Awards” by the French civil society watchdog group l’Observatoire Médicaments Transparences (the Observatory for Transparency in Medicines), for his efforts in negotiating a milestone World Health Assembly resolution in May 2019 supporting more public […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Former Director Of Italian Medicines Agency Recognized For Drug Transparency Work 26/02/2020 Editorial team Former general director of the Italian Medicines Agency (AIFA) Luca Li Bassi was awarded the 2019 “International Transparency in Medicines Policies Awards” by the French civil society watchdog group l’Observatoire Médicaments Transparences (the Observatory for Transparency in Medicines), for his efforts in negotiating a milestone World Health Assembly resolution in May 2019 supporting more public […] Continue reading -> Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Access To Medicines Postponed; UHC, NTDs & Intellectual Property Feature In Next WHO Executive Board Agenda 14/11/2019 Elaine Ruth Fletcher WHO’s agenda for the next Executive Board (EB) meeting, scheduled for 3-8 February 2020, will see discussions grouped for the first time ever around the three key pillars of the WHO Global Plan of Work for 2019-2023, including expanding health and wellbeing, protection from health emergencies, and universal health coverage to one billion more people. […] Continue reading -> “Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
“Delinkage” Of Medicines R&D From Patent Incentives Stirs Debate at Human Rights Council 04/07/2019 Elaine Ruth Fletcher Only a month after a hotly-contested World Health Assembly resolution touched off a debate around “price transparency” as a way to improve access to medicines, a new controversy over how to stimulate access has emerged in another UN Forum, the Human Rights Council. This time the debate is around ways to “delink” incentives for the […] Continue reading -> Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Draft UHC Declaration Strong On R&D Transparency, Weak On R&D Incentives Reform 14/06/2019 David Branigan In the lead-up to the United Nations High-Level Meeting on Universal Health Coverage (UHC) in September, the latest draft of a planned political declaration calls on member states to increase transparency of the cost of research and development (R&D) – in addition to drug prices – but falls short in the area of R&D incentive […] Continue reading -> New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New Drug Transparency Observatory Launched In France 13/06/2019 David Branigan Following the adoption of the World Health Assembly resolution on the transparency of medicines markets last month, a new civil society group has formed in France to monitor the French government’s implementation of the resolution. L’Observatoire Transparence Médicaments (Drug Transparency Observatory), was launched today in a statement calling on the French government and all countries […] Continue reading -> Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Universal Health Coverage: Moving Together, Stronger Together 07/06/2019 Editorial team Githinji Gitahi, Co-Chair of the UHC2030 Steering Committee & Group Chief Executive Officer of AMREF Health Africa – the largest Africa-based healthcare non-profit – and Fumie Griego, Deputy Director General and Chief Operating Officer of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), share highlights from a panel discussion held in Geneva on the […] Continue reading -> WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHA Strengthens Benefit Sharing System For Pandemic Flu Vaccine Development 03/06/2019 Catherine Saez In a little-publicised move, the WHA last week agreed to close a critical loophole in the WHO Pandemic Influenza Preparedness (PIP) Framework that could have allowed commercial vaccine manufacturers to indirectly make use of biological information about flu strains from another country – without providing that country with any benefits from the vaccines or antivirals […] Continue reading -> WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO’s EB Considers New Ways To Work With NGOs – Some Countries Criticise Activists’ Role At WHA 72 30/05/2019 Elaine Ruth Fletcher In the wake of a World Health Assembly that became a focus of intense activist and social media attention over a WHO resolution on medicines price transparency, member states are now looking at new rules for shaping involvement of NGOs and other “non-state actors” at public WHO meetings. Image Credits: WHO. Continue reading -> Posts navigation Older posts